New Zealand - English - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - levobunolol hydrochloride 0.25%{relative};  ;  ;   - eye drops, solution - 0.25 % - active: levobunolol hydrochloride 0.25%{relative}       excipient: benzalkonium chloride dibasic sodium phosphate heptahydrate disodium edetate hydrochloric acid monobasic potassium phosphate polyvinyl alcohol purified water sodium chloride sodium hydroxide sodium metabisulfite

New Zealand - English - Medsafe (Medicines Safety Authority)

abbott laboratories (nz) ltd - glucose 25% - solution for infusion - 25 % - active: glucose 25%

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - estradiol 0.75mg equivalent to 25 µg/24h;   - transdermal patch - 25 mcg/24h - active: estradiol 0.75mg equivalent to 25 µg/24h  

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - estradiol 2mg (releases 25 µg/24 hours);   - transdermal patch - 25 mcg/24h - active: estradiol 2mg (releases 25 µg/24 hours)   excipient: ethanol hyprolose

New Zealand - English - Medsafe (Medicines Safety Authority)

baxter healthcare ltd - glucose monohydrate 25% - solution for infusion - 25 % - active: glucose monohydrate 25% - hypertonic infusion solutions are indicated: - as a source of energy incorporated with parenteral nutrition with minimal dilution effect - for use with an appropriate protein (nitrogen) source in the prevention of nitrogen loss or in the treatment of negative nitrogen balance in patients where: a) the alimentary tract cannot or should not be used b) gastrointestinal absorption of protein is impaired c) metabolic requirements for protein are substantially increased, as with extensive burns.

New Zealand - English - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - bupivacaine hydrochloride monohydrate 0.264% equivalent to 0.25% anhydrous; bupivacaine hydrochloride monohydrate 0.264% equivalent to 0.25% anhydrous - solution for injection - 0.25 % - active: bupivacaine hydrochloride monohydrate 0.264% equivalent to 0.25% anhydrous excipient: sodium chloride sodium hydroxide water for injection active: bupivacaine hydrochloride monohydrate 0.264% equivalent to 0.25% anhydrous excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - marcain solutions are indicated for the production of local or regional anaesthesia and analgesia in individuals as follows: surgical anaesthesia · epidural block for surgery. · field block (minor and major nerve blocks and infiltration). analgesia · continuous epidural infusion or intermittent bolus epidural administration for analgesia in postoperative pain or labour pain. · field block (minor nerve block and infiltration).

Israel - English - Ministry of Health

eli lilly israel ltd - insulin lispro; insulin lispro as protamine - suspension for injection - insulin lispro 25 %; insulin lispro as protamine 75 % - insulin lispro - insulin lispro - humalog mix 25 kwikpen is indicated for the treatment of patients with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Ireland - English - HPRA (Health Products Regulatory Authority)

ovelle limited - benzyl benzoate - cutaneous emulsion - 25 percent weight/volume - other ectoparasiticides, incl. scabicides; benzyl benzoate

Ireland - English - HPRA (Health Products Regulatory Authority)

rottapharm ltd - estradiol - transdermal patch - 25 microgram(s)/24 hours - natural and semisynthetic estrogens, plain; estradiol

Ireland - English - HPRA (Health Products Regulatory Authority)

janssen-cilag ltd - fentanyl - transdermal patch - 25 microgram per hour - phenylpiperidine derivatives; fentanyl